Compare ORI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORI | ROIV |
|---|---|---|
| Founded | 1923 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 20.7B |
| IPO Year | 1994 | 2021 |
| Metric | ORI | ROIV |
|---|---|---|
| Price | $40.61 | $27.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $42.50 | $27.56 |
| AVG Volume (30 Days) | 1.4M | ★ 4.4M |
| Earning Date | 04-23-2026 | 02-06-2026 |
| Dividend Yield | ★ 9.07% | N/A |
| EPS Growth | ★ 14.81 | N/A |
| EPS | ★ 3.72 | N/A |
| Revenue | ★ $9,136,300,000.00 | $29,053,000.00 |
| Revenue This Year | $7.07 | N/A |
| Revenue Next Year | $6.86 | $594.84 |
| P/E Ratio | $10.85 | ★ N/A |
| Revenue Growth | ★ 10.99 | N/A |
| 52 Week Low | $34.53 | $8.91 |
| 52 Week High | $46.76 | $30.33 |
| Indicator | ORI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 53.17 | 49.85 |
| Support Level | $39.17 | $26.45 |
| Resistance Level | $43.54 | $27.94 |
| Average True Range (ATR) | 0.82 | 0.96 |
| MACD | 0.22 | -0.08 |
| Stochastic Oscillator | 93.36 | 60.56 |
Old Republic International Corp is engaged in the business of insurance underwriting and related services. The company operates in two segments: Specialty Insurance and Title Insurance. The insurance provided by the company includes Automobile Extended Warranty Insurance, Aviation, Commercial Automobile Insurance, Inland Marine, Travel Accident, Workers' Compensation, Financial Indemnity, and others. The company generates the majority of its revenue from Specialty Insurance. The Specialty Insurance provides property and liability insurance principally to commercial clients.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.